Mesothelioma, a rare and aggressive cancer caused primarily by asbestos exposure, has seen remarkable treatment advances in recent years. This comprehensive guide covers the latest treatment options, survival statistics, and emerging therapies available in 2026.
Understanding Mesothelioma
Mesothelioma develops in the thin layer of tissue (mesothelium) that covers most internal organs. The most common type is pleural mesothelioma, which affects the tissue surrounding the lungs. Peritoneal mesothelioma affects the abdominal lining and is the second most common form.
Current Treatment Options
1. Immunotherapy
Immunotherapy has revolutionized mesothelioma treatment. The FDA-approved combination of nivolumab and ipilimumab has shown significant improvements in survival rates. This checkpoint inhibitor therapy helps the immune system recognize and attack mesothelioma cells more effectively.
2. Surgical Options
Extrapleural pneumonectomy (EPP) involves removing the affected lung, surrounding tissue, diaphragm, and pericardium. Pleurectomy/decortication (P/D) is a less radical surgery that preserves the lung while removing the diseased pleural tissue.
3. Chemotherapy
The standard first-line chemotherapy regimen combines pemetrexed with cisplatin or carboplatin. Recent studies show that adding bevacizumab to this regimen can improve overall survival in eligible patients.
4. Radiation Therapy
Advanced radiation techniques including intensity-modulated radiation therapy (IMRT) and proton therapy allow precise targeting of mesothelioma tumors while minimizing damage to surrounding healthy tissue.
Clinical Trials and Emerging Therapies
Several promising clinical trials are investigating CAR-T cell therapy, tumor treating fields (TTFields), and novel drug combinations specifically for mesothelioma patients. These experimental treatments offer hope for improved outcomes.
Survival Rates and Prognosis
While mesothelioma prognosis depends on many factors including stage at diagnosis, cell type, and patient health, treatment advances have improved median survival times. Early-stage patients receiving multimodal treatment can achieve survival times exceeding 3-5 years.
Important: If you or a loved one has been diagnosed with mesothelioma, consult with a mesothelioma specialist at a comprehensive cancer center for personalized treatment planning.